Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

被引：0
|
作者：
Borthakur, Gautam [1 ]
Estrov, Zeev [1 ]
Garcia-Manero, Guillermo [1 ]
Williams, Betsy [1 ]
Wathen, Jay K. [1 ]
Konopleva, Marina [1 ]
Burger, Jan [1 ]
Ferrajoli, Alessandra [1 ]
George, Solly [1 ]
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Quantitat Sci Div, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1026 / 1026
页数：1
相关论文
共 50 条
  • [21] TARGETED IMMUNOTHERAPY THERAPY, GEMTUZUMAB OZOGAMICIN, DURING MYELOABLATIVE CONDITIONING FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH POOR-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA
    Satwani, P.
    Moore, V.
    Tallamy, B.
    Bhatia, M.
    Garvin, J.
    George, D.
    Schwartz, J.
    Bradley, M. B.
    van de Ven, C.
    Morris, E.
    Cairo, M. S.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : S10 - S10
  • [22] Gemtuzumab ozogamicin in acute myeloid leukemia
    C D Godwin
    R P Gale
    R B Walter
    [J]. Leukemia, 2017, 31 : 1855 - 1868
  • [23] Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients
    Abdi, Sayed Aliul Hasan
    Shukla, Shatrunajay
    Khan, Jasim
    Al Zahrani, Abdulaziz
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (06)
  • [24] Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia
    Chowdhury, Saeeda
    Seropian, Stuart
    Marks, Peter W.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (09) : 599 - 600
  • [25] Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.
    Mattiuzzi, Gloria
    Amin, Hesham M.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Cortes, Jorge
    [J]. BLOOD, 2009, 114 (22) : 644 - 644
  • [26] Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome
    Matthews, DC
    [J]. LEUKEMIA, 1998, 12 : S33 - S36
  • [27] Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
    Kurt, M
    Shorbagi, A
    Altundag, K
    Elkiran, T
    Güllü, I
    Kansu, E
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2005, 80 (03) : 213 - 215
  • [28] Use of Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
    Walter, Roland B.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S95 - S96
  • [29] Gemtuzumab ozogamicin for treatment of acute myeloid leukemia
    Brotelle, Thibault
    Lemal, Richard
    Molucon-Chabrot, Cecile
    Bay, Jacques-Olivier
    Delaunay, Jacques
    Guieze, Romain
    [J]. BULLETIN DU CANCER, 2014, 101 (02) : 211 - 218
  • [30] Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
    Baron, Jeffrey
    Wang, Eunice S.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (06) : 549 - 559
12345